Highlights Natera, Inc.

Equities

NTRA

US6323071042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
91.66 ^USD	+0.42%		+7.48%	+46.33%

Apr. 18	Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	MT
Apr. 18	Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	Apr. 11	CI
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	Apr. 08	CI
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	Apr. 05	MT
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	Apr. 01	CI
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	Mar. 18	CI
Natera Narrows Q4 Loss, Revenue Rises; Shares Rise Late as 2024 Revenue Outlook Beats Consensus	Feb. 28	MT
Earnings Flash (NTRA) NATERA Posts Q4 Revenue $311.1M, vs. Street Est of $287.3M	Feb. 28	MT
Natera Guides For 2024 Revenue of $1.32-$1.35 Billion, vs CIQ Analyst Consensus of $1.27 Billion	Feb. 28	MT
Natera, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Natera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Medicare Extends Coverage of Natera's Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer	Feb. 26	CI
Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer	Jan. 30	CI
Natera Awarded About $96.3 Million in Patent Infringement Case Against CareDx	Jan. 29	MT
Natera Acquires Reproductive Health Assets From Invitae	Jan. 22	MT
Natera, Inc. completed the acquisition of certain reproductive health assets from Invitae Corporation (NYSE : NVTA) for $52.5 million	Jan. 21	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Policymakers Warn Against Hopes of Large Rate Cuts	Jan. 17	MT
Natera Plans to Appeal After Ravgen Wins Patent Infringement Suit; Shares Rise Premarket	Jan. 17	MT
Natera Plans to Appeal After Ravgen Wins Patent Infringement Suit	Jan. 16	MT
Natera Reports Higher Q4, 2023 Preliminary Revenue	Jan. 09	MT
Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023	Jan. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Natera, Inc.

Equities

NTRA

US6323071042

Highlights

Filters